Skip to main content
Premium Trial:

Request an Annual Quote

MiRagen Hits First Milestone in Servier microRNA Drug Partnership

Premium

MiRagen Therapeutics this week said it has achieved the first milestone in its partnership with Les Laboratoires Servier, with the French company selecting a third target for microRNA drug development.

The move triggered an undisclosed milestone payment to MiRagen.

In late 2011, the companies agreed to jointly develop two of MiRagen’s miRNA antagonists including one designed to silence miR-208 for chronic heart failure and one that targets miR-15/miR-195 to treat post-myocardial infarction remodeling (GSN 11/20/2011).

That deal, which is valued for MiRagen at $45 million over three years — and could be worth up to $1 billion if all clinical and commercial milestones are met — also gave Servier the option to a yet-to-be-named third drug candidate. Now Servier has selected the drug target for that third compound.

Additional details were not disclosed.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.